Expression of EGFR > 35% was associated with the presence of lymph node metastases (p = 0.001), liver metastases at diagnosis (p < 0.001), advanced stages of the disease (p < 0.001) and KRAS mutations (p = 0.001). Here, EGFR is linked to metastatic malignant neoplasm in the lymph nodes.